Marx CE, Keefe RS et al (2009)
The combination of SGLT-2 inhibitors and GLP-1 RAs offer additive benefits in reducing cardiovascular and renal risk in patients with diabetes and should be considered
A compromised sequence in either compound can competitively occupy receptor sites without producing the intended signaling activity, corrupting research outcomes and, in impure gray-market material, introducing toxic byproducts into sensitive laboratory models
It does not raise VO2max, increase hematocrit, or directly improve power output
10.1186/s12903-019-0884-4 60
Custom blends Carnitine combined with electrolytes, amino acids, or botanical extracts